Adiponectin and Insulin Resistance in Diabetic Nephropathy

Diabetic Nephropathy Clinical Trial

Official title:

Adiponectin is Positively Associated With Insulin Resistance in Subjects With Type 2 Diabetic Nephropathy and Effects by Angiotensin Type 1 Receptor Blocker Losartan

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00774904
• Other study ID #: ADPN
• Status: Completed
• Phase: N/A
• First received: October 16, 2008
• Last updated: October 17, 2008
• Start date: April 2007
• Est. completion date: November 2007

Study information

• Verified date: October 2008
• Source: Xi’an Jiaotong University College of Medicine
• Contact: n/a
• Is FDA regulated: No
• Health authority: China: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Plasma adiponectin concentration is inversely associated with renal function. There is little literature on adiponectin levels and regulation by antihypertensive medication with an angiotensin II-receptor blocker (ARB), especially in subjects with type 2 diabetes in different stage of chronic kidney disease (CKD).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 80
• Est. completion date: November 2007
• Est. primary completion date: October 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Type 2 diabetic nephropathy

• CKD at stage 1~4

Exclusion Criteria:

• Type 1 diabetes or nondiabetic renal disease

• An elevated plasma K level.

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetic Nephropathies
• Diabetic Nephropathy
• Insulin Resistance
• Kidney Diseases

Intervention

Drug:
• Losartan
Angiotensin II Type 1 Receptor Blockers

Locations

Country	Name	City	State
China	Shanghai No.3 people's hospital	Shanghai

Sponsors (2)

Lead Sponsor	Collaborator
Xi’an Jiaotong University College of Medicine	Shanghai Jiao Tong University School of Medicine

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	GFR, HbA1c and the adiponectin concentration		6 month	Yes